Normothermic Machine Perfusion of Steatotic Livers for Expansion of Donor Organ Pool

Description

The goal of this clinical trial is to assess the ability of Normothermic Machine Perfusion (NMP) to resuscitate moderately steatotic livers for transplantation in patients. This will be a single-site clinical trial placing donor livers with 30-60% macrosteatosis on NMP, and then transplanting those that meet commonly accepted viability criteria. The results of this study could lead to a trial extending NMP transplantation to severely steatotic livers, further expanding the donor organ pool.

Conditions

Liver Transplant

Study Overview

Study Details

Study overview

The goal of this clinical trial is to assess the ability of Normothermic Machine Perfusion (NMP) to resuscitate moderately steatotic livers for transplantation in patients. This will be a single-site clinical trial placing donor livers with 30-60% macrosteatosis on NMP, and then transplanting those that meet commonly accepted viability criteria. The results of this study could lead to a trial extending NMP transplantation to severely steatotic livers, further expanding the donor organ pool.

Normothermic Machine Perfusion of Steatotic Livers for Expansion of Donor Organ Pool

Normothermic Machine Perfusion of Steatotic Livers for Expansion of Donor Organ Pool

Condition
Liver Transplant
Intervention / Treatment

-

Contacts and Locations

Boston

Massachusetts General Brigham, Boston, Massachusetts, United States, 02114

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Age 18-80 years
  • * Listed for liver transplantation at MGH
  • * Calculated MELD-Na score \<= 25
  • * Able to consent
  • * Status 1a
  • * Cardiac or pulmonary disease
  • * Prior liver transplant
  • * Requiring pressors at the time of liver offer
  • * MELD\<15 and asymptomatic from liver disease

Ages Eligible for Study

18 Years to 80 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Massachusetts General Hospital,

Study Record Dates

2026-11